|
|
|
|
|
|
Sponsored by: |
Novartis |
Information provided by: | Novartis |
ClinicalTrials.gov Identifier: | NCT00409851 |
A ONE YEAR SAFETY STUDY FOR PATIENTS WHO COMPLETE STUDY VAA489A2201.
Condition | Intervention | Phase |
Hypertension |
Drug: valsartan+amlodipine |
Phase III |
MedlinePlus related topics: | High Blood Pressure |
Drug Information available for: | Valsartan Amlodipine Amlodipine besylate Exforge |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Uncontrolled, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A 52 Week, Open Label Extension to the Randomized, Double-Blind, Multicenter, Multifactorial, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Valsartan and Amlodipine Combined and Alone in Hypertensive Patients. |
Estimated Enrollment: | 1850 |
Study Start Date: | April 2003 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, New Jersey | |||||
Novartis Pharmaceuticals | |||||
East Hanover, New Jersey, United States, 07936 | |||||
Germany | |||||
Sites in Germany, Germany |
Novartis |
Study Chair: | Novartis pharmaceuticals | Sponsor GmbH |
NOVARTIS PATIENT RECRUITMENT WEBSITE 
  |
Study ID Numbers: | CVAA489A2201E1 |
First Received: | December 7, 2006 |
Last Updated: | July 6, 2007 |
ClinicalTrials.gov Identifier: | NCT00409851 |
Health Authority: | United States: Food and Drug Administration |
|
|
|
|